Margarita Chavez is a seasoned biopharmaceutical executive, with over 25 years of dealmaking experience in the healthcare industry. She is currently a Venture Partner at Wellington Partners and is an independent investor and advisor in early-stage biotechs. Margarita also currently serves on the Board of Newron Pharmaceuticals (NWRN:SIX). Margarita was previously Managing Director at AbbVie Ventures and was responsible for investments in Morphic Therapeutics, Alector Therapeutics, Carisma Therapeutics, Jnana Therapeutics, Enthera Pharmaceutials, Palleon Pharmaceuticals, and Accent Therapeutics, among others. As a Director on the Licensing & Acquisitions team of Abbott / AbbVie, Margarita was involved in the in-licensing of Oralissa, and the acquisitions of Immuven and Solvay. Early in her career, Margarita practiced as a corporate and securities lawyer, advising clients on mergers, acquisitions, public and private financings at Brobeck, Phleger & Harrison LLP in Silicon Valley. Outside of her venture work, Margarita serves on the Board of Regents at Santa Clara University and on the Board of P33 Chicago.